Atrial Dysfunction Assessed by Cardiac Magnetic Resonance as an Early Marker of Fabry Cardiomyopathy

Authors :: Andrea Bernardini
Francesca Carubbi
Maurizio Pieroni
Yuri Battaglia
Kelvin Chow
Alessandro P. Burlina
Marco Spada
Paola Lusardi
Silvia Pica
Renzo Mignani
Stefano Figliozzi
Massimo Lombardi
Francesca Graziani
Lara Tondi
Sara Boveri
Iacopo Olivotto
Antonia Camporeale
Federico Pieruzzi
Bernardini, A
Camporeale, A
Pieroni, M
Pieruzzi, F
Figliozzi, S
Lusardi, P
Spada, M
Mignani, R
Burlina, A
Carubbi, F
Battaglia, Y
Graziani, F
Pica, S
Tondi, L
Chow, K
Boveri, S
Olivotto, I
Lombardi, M
Publication Year :: 2020
Abstract: Anderson-Fabry disease (AFD) cardiomyopathy is characterized by glycosphingolipid (Gb3) storage in all cellular components, with consequent left ventricular hypertrophy (LVH). Gb3 accumulation also involves atrial myocytes ([1][1]), ultimately leading to left atrial (LA) enlargement and reduced

Subjects :: medicine.medical_specialty
Magnetic Resonance Spectroscopy
Cardiomyopathy
030204 cardiovascular system & hematology
Anderson-Fabry disease
030218 nuclear medicine & medical imaging
Muscle hypertrophy
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Left atrial
Predictive Value of Tests
Internal medicine
Medicine
Humans
Radiology, Nuclear Medicine and imaging
Fabry disease, cardiomyopathy, atrial dysfunction, cardiac magnetic resonance, T1 mapping
cardiovascular diseases
Atrial myocytes
Heart Atria
LA strain
business.industry
Anderson-Fabry disease, T1 mapping, LA strain
Glycosphingolipid
T1 mapping
medicine.disease
Anderson-Fabry Disease
chemistry
Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE
cardiovascular system
Cardiology
Cardiology and Cardiovascular Medicine
business
Cardiac magnetic resonance
Cardiomyopathies

Tools